Drug Type Small molecule drug |
Synonyms AgaDerm, AgaNase, DCDMT + [3] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC4H9Cl2NO3S |
InChIKeyQYNRGGHZWCUZLK-UHFFFAOYSA-N |
CAS Registry846056-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Impetigo | Phase 3 | United States | 01 Aug 2012 | |
Impetigo | Phase 3 | South Africa | 01 Aug 2012 | |
Conjunctivitis, Bacterial | Phase 2 | United States | 01 Jun 2013 | |
Urinary Bladder, Neurogenic | Phase 2 | United States | 01 Nov 2010 | |
Acne Vulgaris | Phase 2 | United States | 01 Apr 2010 | |
Acne Vulgaris | Phase 2 | United States | 01 Apr 2010 | |
Adenoviral Conjunctivitis | Phase 2 | - | 01 Jun 2009 | |
Catheter-Related Infections | Phase 2 | United States | 29 Oct 2008 | |
Escherichia Coli Infections | Preclinical | United States | - | |
Klebsiella Infections | Preclinical | United States | - |